SWOG-9510: Evaluation of topotecan in hormone refractory prostate cancer: A Southwest Oncology Group study

Prostate

Volumn 52, Issue 4, 2002, Pages 264-268

  Klein, Catherine E ^a,h   Tangen, Catherine M ^b   Braun, Thomas J ^a   Hussain, Maha H A ^c   Peereboom, David M ^d   Nichols, Craig R ^e   Rivkin, Saul E ^f   Dakhil, Shaker R ^g   Crawford, E David ^a  

^a UNIVERSITY OF COLORADO   (United States)

^b SOUTHWEST ONCOLOGY GROUP STATISTICAL CENTER   (United States)

^c WAYNE STATE UNIVERSITY   (United States)

^d LERNER RESEARCH INSTITUTE   (United States)

^e OREGON HEALTH AND SCIENCE UNIVERSITY   (United States)

^f Fred Hutchinson Cancer Research Center   (United States)

^g WICHITA COMMUNITY CLINICAL ONCOLOGY PROGRAM   (United States)

^h VETERANS AFFAIRS MEDICAL CENTER   (United States)

Author keywords

Clinical trial; Hormone refractory prostate cancer; Topotecan

Indexed keywords

ANDROGEN; DNA TOPOISOMERASE INHIBITOR; TOPOTECAN;

ADULT; AGED; ALOPECIA; ANEMIA; ARTICLE; BLOOD TOXICITY; CANCER CHEMOTHERAPY; CANCER HORMONE THERAPY; CANCER SURVIVAL; CLINICAL ARTICLE; CLINICAL TRIAL; CONFUSION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DIARRHEA; DISEASE SEVERITY; DRUG EFFICACY; EPISTAXIS; FATIGUE; FEVER; HEMATURIA; HUMAN; LEUKOPENIA; MALE; NAUSEA; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; PROSTATE CANCER; STOMATITIS; THROMBOCYTOPENIA; VOMITING;

AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS; DRUG RESISTANCE, NEOPLASM; HUMANS; INFUSIONS, INTRAVENOUS; MALE; MIDDLE AGED; PROSTATIC NEOPLASMS; SURVIVAL ANALYSIS; TOPOTECAN; TREATMENT OUTCOME;

EID: 0036720932     PISSN: 02704137     EISSN: None     Source Type: Journal    
DOI: 10.1002/pros.10118     Document Type: Article

References (19)

1. 125I implantation
2. Results of conservative management of clinically localized prostate cancer
3. High dose bicalutamide for androgen independent prostate cancer: Effect of prior hormonal therapy
4. Megestrol acetate in the treatment of hormone refractory prostate cancer
5. Ketoconazole retains activity in advanced prostate cancer patients with progression despite flutamide withdrawal
6. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer
7. Chemotherapy with mitoxantrone plus prednisone or prednisone alone for symptomatic hormone-resistant prostate cancer. A Canadian randomized trial with palliative end-points
8. Phase II trial of 96-hour paclitaxel plus oral estramustine phosphate in metastatic hormone-refractory prostate cancer
9. DNA topoisomerase I targeted chemotherapy of human colon cancer in xenografts
10. Evaluation of 9-dimethylaminomethyl-10-hydroxycamptothecin (Topotecan) against xenografts derived from adult and childhood tumors
11. A model for tumor cell killing by topoisomerase poisons
12. Action of camptothecin on mammalian cells in culture
13. Phase II study of topotecan in metastatic hormone-refractory prostate cancer
14. Phase I clinical and pharmacologic study of topotecan given daily for 5 consecutive days to patients with advanced solid tumors, with attempts at dose intensification using recombinant granulocyte colony stimulating factors
15. Phase I and pharmacologic studies of topotecan, a novel topoisomerase inhibitor
16. Phase I trial of low-dose continuous topotecan infusion in patients with cancer: An active and well-tolerated regimen
17. Prostate-specific antigen as a measure of disease outcome in metastatic hormone refractory prostate cancer
18. Docetaxel (Taxotere) as monotherapy in the treatment of hormone-refractory prostate cancer
19. Phase II trial of estramustine, oral etoposide, and intravenous paclitaxel in hormone-refractory prostate cancer